SLC5A2 and type 2 diabetes mellitus: For example, we found that SGLT2 inhibitors could reduce the ALT values (− 8.9 U/l, 95% CI − 17.0 to − 0.9) while DPP4 inhibitors did not significantly improve the ALT (− 3.8 U/l, 95% CI − 15.8 to 8.2) in type 2 diabetes patients with liver cirrhosis after 1-year treatment (data not shown).